sorafenib has been researched along with cyproheptadine in 3 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (cyproheptadine) | Trials (cyproheptadine) | Recent Studies (post-2010) (cyproheptadine) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 2,297 | 262 | 201 |
| Protein | Taxonomy | sorafenib (IC50) | cyproheptadine (IC50) |
|---|---|---|---|
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 0.0024 | |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 0.564 | |
| Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | 0.035 | |
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | 0.016 | |
| 5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | 0.0031 | |
| Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | 0.0038 | |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | 0.283 | |
| Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | 0.016 | |
| D(2) dopamine receptor | Homo sapiens (human) | 0.164 | |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | 0.0031 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.038 | |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | 1.275 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.122 | |
| Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | 0.046 | |
| D(1A) dopamine receptor | Homo sapiens (human) | 0.158 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 0.564 | |
| Histamine H2 receptor | Homo sapiens (human) | 0.198 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.107 | |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 0.001 | |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 0.0024 | |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 0.122 | |
| 5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | 0.0031 | |
| Histamine H1 receptor | Homo sapiens (human) | 0.0037 | |
| D(3) dopamine receptor | Homo sapiens (human) | 0.048 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.0094 | |
| 5-hydroxytryptamine receptor 6 | Homo sapiens (human) | 0.281 | |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 0.14 | |
| Histone-lysine N-methyltransferase SETD7 | Homo sapiens (human) | 2.2 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, G; Huang, N; Huang, XP; Lin, X; Peng, S; Roth, BL; Wang, S; Wang, SX; Wang, Y; Whaley, R; Zhang, G | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Chen, CY; Chen, SC; Feng, CW; Feng, YM; Lee, MY; Lu, CL | 1 |
1 review(s) available for sorafenib and cyproheptadine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 other study(ies) available for sorafenib and cyproheptadine
| Article | Year |
|---|---|
Life beyond kinases: structure-based discovery of sorafenib as nanomolar antagonist of 5-HT receptors.
Topics: Antineoplastic Agents; Benzenesulfonates; Cyproheptadine; Drug Approval; Drug Discovery; Ketanserin; Molecular Dynamics Simulation; Niacinamide; Phenylurea Compounds; Protein Conformation; Pyridines; Receptors, Serotonin; Sequence Homology, Amino Acid; Serotonin Antagonists; Sorafenib; United States; United States Food and Drug Administration; User-Computer Interface | 2012 |
Cyproheptadine significantly improves the overall and progression-free survival of sorafenib-treated advanced HCC patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Case-Control Studies; Cyproheptadine; Disease Progression; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib | 2015 |